Pembrolizumab in locally advanced sinonasal carcinoma - NeoPeSino
- Conditions
- ocally advanced sinonasal carcinomaTherapeutic area: Diseases [C] - Otorhinolaryngologic Diseases [C09]
- Registration Number
- CTIS2023-505917-25-00
- Lead Sponsor
- Istituti Clinici Scientifici Maugeri In Forma Abbreviata Istituti Clinici Scientifici Maugeri O Anche Ics Maugeri O Maugeri S.p.A. Sb
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 28
1.Have centrally histologically-confirmed, treatment-naïve SNUC that is considered curable by local therapies. Resectability at diagnosis should be recorded on the electronic case report form (eCRF) but is not a required inclusion criteria. 2.Have locally advanced disease defined as stage III of IVa-b according to AJCC cancer staging system VIII edition. 3.Be willing and able to provide written informed consent for the trial. The subject may also provide consent for Future Biomedical Research. However, the subject may participate in the main trial without participating in Future Biomedical Research. 4.Be = 18 years of age on day of signing informed consent. 5.Have measurable disease based on RECIST 1.1 as determined by the site. 6.Have a performance status of 0 or 1 on the ECOG Performance Scale. 7.Demonstrate adequate organ function as defined in Table 4, all screening labs should be performed within 15 days of treatment initiation. 8.A male participant must agree to use a contraception as detailed in Appendix 3 of this protocol during the treatment period and for at least 180 days, corresponding to time needed to eliminate any study treatments plus an additional 90 days (a spermatogenesis cycle) for study treatments with evidence of genotoxicity at any dose after the last dose of study treatment and refrain from donating sperm during this period. 9.A female participant is eligible to participate if she is not pregnant (see Appendix 3), not breastfeeding, and at least one of the following conditions applies: a.Not a woman of childbearing potential (WOCBP) as defined in Appendix 3 OR b.A WOCBP who agrees to follow the contraceptive guidance in Appendix 3 during the treatment period and for at least 180 days (corresponding to time needed to eliminate any study treatments plus 30 days (a menstruation cycle) for study treatments with risk of genotoxicity after the last dose of study treatment.. 10.Have provided tumor tissue sample or newly obtained core or excisional biopsy of a tumor lesion. Formalin-fixed, paraffin embedded (FFPE) tissue blocks are preferred to slides. Newly obtained biopsies are preferred., 2.Have locally advanced disease defined as stage III of IVa-b according to AJCC cancer staging system VIII edition., 5. Have measurable disease based on RECIST 1.1 as determined by the site., 6.Have a performance status of 0 or 1 on the ECOG Performance Scale.
1.Has disease that is deemed not suitable for local therapy administered with curative intent (e.g. severe brain involvement)., 2.Have metastatic disease defined as stage IVc according to AJCC cancer staging system VIII edition., 4.Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti PD L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (eg, CTLA-4, OX 40, CD137)., 5.Has received prior systemic anti-cancer therapy including investigational agents prior to allocation.
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method